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Relation of inflammation and cancer can be proven in most of the studies. 
Epidermal growth factor receptor (EGFR) overexpression is one of the 
commonest causes of non-small cell carcinoma of lung cancer (NSCLC). 
Cyclooxygenase-2 (COX-2) enzyme and its products; prostaglandin, 
prostacyclin, thromboxane are involved in inflammation. The aim of the 
study was to compare the serum epidermal growth factor receptor and 
cyclooxygenase-2 levels between patients with non-small cell carcinoma of 
lung and healthy controls. This study included 53 patients diagnosed as 
NSCLC and 16 apparently healthy controls. In 53 patients, 3 patients were 
diagnosed as adenocarcinoma and 50 patients were diagnosed as squamous 
cell carcinoma (SCC) of lung. In both subjects, serum EGFR and COX-2 
levels were determined by ELISA. The mean serum EGFR and COX-2 
levels of NSCLC patients were significantly higher than those of healthy 
controls (170.10±13.80 vs. 3.56±0.48 ng/ml) and (13.21±3.17 vs. 0.62±   
0.15 ng/ml), respectively (p<0.001 in both). Both the mean serum EGFR 
and COX-2 levels of SCC patients (172.10±14.30 ng/ml and 13.60±3.34 
ng/ml) were significantly higher than those of healthy controls (p<0.001 in 
both). Both serum EGFR levels and COX-2 levels of patients with adeno-
carcinoma of lung (137.40±64.70 ng/ml and 6.69±5.52 ng/ml) were          
not significantly different with those of healthy controls (p=0.174 and   
p=0.386), respectively. The mean serum EGFR and COX-2 levels of SCC 
patients were higher than those of adenocarcinoma patients but they were                
not significant (p=0.653 and p=0.363), respectively. These findings indicated 
that EGFR and COX-2 play an important role in carcinogenesis of lung.  
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INTRODUCTION 
 
Carcinoma of the lung is the leading cause 
of death worldwide and has a poor 
prognosis. Dysregulation of key pathways 
involved in cellular growth and apoptosis 
results in tumorigenesis. Epidermal growth 
factor receptor (EGFR) is one of the 
products of protooncogenes. EGFR is a kind 
of receptor tyrosine kinase expressed on the 
surface of epithelial cells. EGFR regulates 
vital cellular processes such as proliferation, 
migration, survival and angiogenesis.1 
 
Many chronic skin inflammation or irrita-
tions are known to be associated with 
increased prevalence of squamous cell 
carcinoma.2 Cyclooxygenase-2 (COX-2) is 
an inducible enzyme stimulated by cyto-
kines, growth factors, oncogenes, or tumor 
promoters during inflammation or malig-
nancy. The carcinogenic effect of COX-2 
mainly exerted through the increase level of 
prostaglandin.3 It results in decreased 
apoptosis, increased tumor invasiveness, 
immunosuppression and angiogenesis.4 
 
Involvement of these two molecules in 
carcinogenesis is determined by immuno-
histochemistry (IHC) method  in  vitro studies 
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or cancers other than lung cancer. In this 
study, determination of EGFR and COX-2 
levels were done by ELISA methods in the 
serum of patients with NSCLC.  
 
MATERIALS AND METHODS 
 
It was cross-sectional descriptive study 
conducted from December 2010 to June 
2014. A total 53 numbers of patients 
diagnosed as NSCLC by histology and 
cytology reports by the pathologist were 
collected from Department of Respiratory 
Medicine and Department of Thoracic 
Surgery, Yangon General Hospital were 
included. Sixteen numbers of apparently 
healthy adults who lived in Lanmadaw 
Township and worked at Department of 
Biochemistry, University of Medicine 1 
(Yangon) were selected as control.  
Both men and women patients and normal 
subjects were included. But the patients  
who had renal or hepatic failure with      
high serum creatinine or liver enzymes, 
pulmonary tuberculosis, autoimmune disease, 
other inflammatory diseases and other mali-
gnancies and patients who were taking 
NSAID and or steroid drugs within 3 weeks 
were excluded from the study.  
After taking informed consent, history and 
physical examination, 5 ml of blood were 
collected and serum were stored at -80°C 
before analysis. Determination of serum 
EGFR and COX-2 were done at Nuclear 
Medicine Research Division, Department of 
Medical Research (Lower Myanmar) by 
ELISA method which was a quantitative 
sandwich immunoassay and both kits were 
products of Uscn Life Science, USA.  
 
Data entry was done in Microsoft Excel and 
data analysis was done by using the 
Statistical Package for Social Science 
(SPSS) software version 16. Standard 
statistical methods were applied for the 
calculation of mean, standard error of the 
mean and standard deviation. Comparison 
of the serum EGFR and COX-2 levels was 
analyzed by unpaired ‘t’ test. Significant 
level was decided if the probability levels of 
all tests were <0.05. 
 
Ethical consideration  
 
The proposal of this research was approved 
by Ethic and Research Committee, University 
of Medicine 1 on 18th January, 2012. 
 
RESULTS 
 
Table1. Comparison of serum EGFR and 
COX-2 levels of healthy control and 
NSCLC patients 
 
 
 
Parameter 
 
 
p value 
 
 
Serum EGFR level (ng/ml) 
 
 
 
Healthy control (n=16) 
3.56±0.48 (0.19-5.47) 
 
 
 
NSCLC# (n=53) 
170.10±13.80 (4.14-439.20) 
 
 
<0.001 
 
 
Healthy control (n=16) 
 
 
 
SCC# (n=50) 
172.10±14.30 (4.14-439.20) 
 
 
 
 
<0.001 
 
 
Healthy control (n=16) 
 
 
 
Adenocarcinoma#  (n=3) 
137.40±64.70 (64.70-266.40) 
 
 
 
0.174 
 
 
SCC# (n=50) 
 
 
Adenocarcinoma# (n=3) 
 
 
0.653 
 
Serum COX-2 level (ng/ml) 
 
 
 
Healthy control (n=16) 
0.62±0.15 (0.00-2.03) 
 
 
 
NSCLC# (n=53) 
13.21±3.17 (0.49-145.70) 
 
 
<0.001 
 
 
Healthy control (n=16) 
 
 
 
SCC# (n=50) 
13.60±3.34 (0.49-145.70) 
 
 
<0.001 
 
 
Healthy control (n=16) 
 
 
 
Adenocarcinoma# (n=3) 
6.69±5.52 (0.78-17.73) 
 
 
 
0.386 
 
 
SCC#  (n=50) 
 
 
 
Adenocarcinoma#  (n=3) 
 
 
 
0.363 
 
#=Patients, data were shown in Mean±SEM (range). 
 
Age (mean±SD) of healthy controls, patients 
with NSCLC, SCC and adenocarcinoma of 
lung are 56.38±10.17 years (range=40-73), 
60.83±9.62 years (range=27-79), 60.66±9.85 
years (range=27-79) and 63.67±3.51 years 
(range=60-67), respectively. There is no 
significant difference in age between healthy 
controls and patients with NSCLC or SCC or 
adenocarcinoma of lung (p=0.134, p=0.152 
and p=0.052), respectively. In healthy control 
group, majority (63%) were females but in 
NSCLC patients, majority (70%) were males. 
 
DISCUSSION 
 
Lung cancer was the most commonly 
diagnosed cancer worldwide and had 12.9% 
(1.8 million) of the total new cancer cases.  
It was also the most common causes of 
cancer death and had 19.4% (1.6 million) of 
the total cancer-related deaths.5 
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For therapeutic purposes, carcinomas of the 
lung are classified into two broad groups: 
small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). SCLC and 
NSCLC are clinically and genetically 
distinct. SCLCs are best treated by chemo-
therapy because all are metastatic to other 
tissues. By contrast, NSCLCs are curable by 
surgery if limited to the lung. 
 
EGFR normally involves in cell growth, 
proliferation, cell division, differentiation 
and apoptosis. Over-expression or mutation 
of EGFR activates cellular signaling path-
ways that induce characteristics of cancer 
cells, including angiogenesis, metastasis, 
and invasiveness. Thus, EGFR is as target 
of therapy and have been implicated in 
disease progression, decreased survival, and 
resistance to cytotoxic agents or radiation. 
COX-2 and its products prostaglandin        
are known to play an important role             
in carcinogenesis by stimulating growth, 
survival, invasion, metastasis, and angio-
genesis of tumor cells.  
 
In the present study, the mean serum    
EGFR level in healthy control was 3.56±            
0.48 ng/ml and in NSCLC patients was 
170.10±13.8 ng/ml. The mean serum EGFR 
level of NSCLC patients was significantly 
higher than that of healthy controls 
(p<0.001). The mean serum EGFR level in 
SCC lung patients was also significantly 
higher than that of healthy controls 
(p<0.001). The mean serum EGFR level of 
adenocarcinoma patients was much higher 
than that of healthy controls and it could not 
be concluded that it was not statistically 
significant (p>0.174) because the number of 
adenocarcinoma patients was only 3.  
 
The similar results were seen in other 
studies, however, the method of EGR 
determination was different. Zhu, et al and 
Li, et al in China reported that EGFR 
expression in primary lung cancer tissues 
was significantly higher than those of the 
control although EGFR expression was 
detected by IHC method.6, 7 In the study of 
Fujino, the mean EGFR level in primary 
non-small cell lung cancer tissues was 
significantly higher than in normal tissues 
but serum EGFR level was measured by 
using a competitive radiolig and binding 
assay.8 
Increased serum EGFR level in carcinoma 
of lung may be due to EGFR over-
expression. Over-expression of EGFR can 
occur by amplification or mutation of  
EGFR gene. But Dacic, et al found that 
EGFR over-expression in NSCLC was 
uncoupled with gene amplification.9 Three 
polymorphisms that are associated with 
EGFR over-expression are a polymorphic 
dinucleotide repeat (CA simple sequence 
repeat 1 [CA-SSR1]) in intron one (lower 
number of repeats) and two single nucleo-
tide polymorphisms in the promoter region, 
-216 (G/T or T/T) and -191 (C/A or A/A).10 
There were also other studies which results 
were inconsistent with those of the present 
study. In the study of Lemos-Gonzalez and 
colleagues, the mean serum EGFR level of 
NSCLC patients was significantly decreased 
than that of healthy subjects.11  Schneider,  
et al found that there was no significant 
difference in serum EGFR levels in patients 
with lung caners and healthy controls.12 
Decreased or no difference in serum     
EGFR level in carcinoma of lung may be 
due to different activity of metalloprotease 
enzymes. EGFR extracellular domains and    
its ligands are shed from membrane by 
membrane anchored proteases, a family of a 
disintegrin and metalloproteinase (ADAM). 
The proteolytic activity of ADAM can be 
influenced by factors such as osmotic and 
mechanical stress, G protein-coupled receptor 
activation, activation of proteinkinase C, 
increase in intracellular calcium, serum 
factors and growth factors.13 
In the present study, serum EGFR levels in 
patients with SCC of the lung were higher 
than those of patients with adenocarcinoma 
lung but it can’t be compared because the 
number of adenocarcinoma lung patients 
was only 3. The similar pattern of result was 
obtained, however, EGFR expression was 
determined on tumor cells by IHC method 
rather than ELISA. In the study of Veale,   
14 
et al in which EGFR was most commonly 
found in SCC (70%) followed by adenocar-
cinoma (50%).14 Dacic and coworkers also 
found that EGFR protein expression was 
more common in SCC (26.2%) than in ade-
nocarcinoma (11.1%) (p=0.0076).9 EGFR 
expression in SCC of lung was more fre-
quently associated with EGFR amplification 
than adenocarcinoma lung (14.5%) vs. 
(3.6%) cases (p=0.0208). 
 
In the present study, the mean serum COX-2 
level of NSCLC patients (0.62±0.15 ng/ml) 
was significantly higher than that of healthy 
controls (13.21±3.17 ng/ml) (p<0.001). In 
most of the studies, COX-2 expression was 
detected by IHC in lung tissues rather than 
serum by ELISA. Li and colleagues (2011) 
found that COX-2 expression was 90% for 
NSCLC tumors and was significantly higher 
than that for normal lung (0%).7 Zhu, Liu 
and Wang detected that COX-2 expression 
in primary lung cancer tissues (52.8%) was 
significantly higher than those of the control 
(p<0.05).6 In the present study, mean serum 
COX-2 level in patients with SCC of the 
lung was higher than that of patients with 
adenocarcinoma of the lung but it was not 
significant (p=0.363). It was not consistent 
with the studies that COX-2 expression was 
found more in adenocarcinoma than SCC of 
lung.7, 15 
 
The higher serum COX-2 level in SCC than 
adenocarcinoma of lung in the present study 
may be due to large difference in number of 
cases between adenocarcinoma cases (n=3) 
and SCC cases (n=50). Another explanation 
for this discrepancy was COX-2 expression 
was measured by IHC in the previous 
studies and serum COX-2 was measured by 
ELISA in the present study. Since COX-2 
enzyme is located at the luminal side of     
the endoplasmic reticulum and nuclear 
membrane, it can’t be detected in the serum 
until the cells are destroyed.16 Therefore, 
serum COX-2 level may not reflect its 
actual expression in cancer cells.  
 
The findings of the present study indicated 
that both EGFR and COX-2 have impli-
cation in development of NSCLC and can 
be applied in further research in relation 
between cancer and inflammation. But in 
the present study, EGFR and COX-2 
expressions couldn’t be measured in the 
tissue samples. Therefore, applicability of 
measuring serum COX-2 as an additional 
serum marker for diagnosis of non small 
cell carcinoma of lungs is not sure     
although measuring serum EGFR may 
applicable. Further studies are necessary for 
confirmation. 
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